PT-141 for HSDD
A tanning-family relative became bremelanotide. Its clinical purpose is unusually specific.
From melanocortins to HSDD
PT-141 is bremelanotide, a synthetic cyclic peptide related to melanotan II and to the body’s melanocortin signals. The earlier tanning work helps explain its chemical ancestry; the eventual U.S. indication is acquired, generalized hypoactive sexual desire disorder in premenopausal women. HSDD refers to low sexual desire associated with distress.
I enjoy bremelanotide’s unlikely change of direction. Here the destination matters more than the surprise: the approved medicine addresses that diagnosis in that population. Use in men, postmenopausal women or for sexual-performance enhancement falls outside the approval.
RECONNECT trials
The two randomized Phase 3 trials enrolled 1,267 premenopausal women with HSDD. Over 24 weeks, bremelanotide improved the sexual-desire score and reduced distress about low desire compared with placebo. The integrated desire-score difference was +0.35, with P<.001. A statistically significant difference says that the trial detected an effect; its practical importance still involves how participants experienced the change.
The 52-week open-label extension enrolled 684 women and reported no new safety signals. Nausea occurred in 40.4%, flushing in 20.6% and headache in 12.0%. An extension with no placebo comparison answers a different question from the original randomized trials. I appreciate having those women followed for longer, while remaining conscious of who continued into the extension.
Syrian hamster experiment
A 2025 experiment in female Syrian hamsters produced a useful complication. Bremelanotide did not enhance sexual reward in the conditioned-place-preference test, which examines an animal’s learned preference for a place associated with an experience. It also left melanocortin-receptor mRNA expression unchanged in the studied dopamine reward system.
That animal result concerns this model and those measurements. It cannot cancel the human desire trials. For me, it makes the broad phrase “increases sexual pleasure” much too casual: desire, distress and reward are different things to investigate.
Human brain imaging
The crossover fMRI study in 31 premenopausal women with HSDD found increased sexual desire for up to 24 hours and changes in brain responses to erotic stimuli after MC4R agonism. The observations support a central action on sexual processing. They give the clinical story a plausible mechanism without turning a brain scan into a measure of a person’s whole sexual life.
That limited, interesting question suits the molecule better than its online reputation as a universal enhancer.
Bremelanotide safety
The prescribing information warns of transient blood-pressure increases and contraindicates use in uncontrolled hypertension or known cardiovascular disease. It also describes pigmentation changes with frequent use that may not fully reverse. Nausea is a major tolerability problem in the longer-term study.
Community accounts range from renewed interest and arousal to nausea with no perceived benefit. They are anecdotal reports, not clinical evidence for a broader indication. I mistrust an appeal to chemical ancestry when it is used to carry an approved indication into any population or product form.